ATXI — Avenue Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.27m
- -$0.67m
- $1.40m
Brief: Annji Pharma Entered Into An Exclusive License Agreement With Avenue Therapeutics
U.S. STOCKS ON THE MOVE-Vertex Pharma, Duluth, Molecular Templates
U.S. STOCKS ON THE MOVE-BJ's Wholesale, FuelCell Energy, Holley
Avenue Therapeutics up on meeting FDA to discuss drug administration study
Brief: Avenue Therapeutics Inc - On March 7, Board Voted To Expand Size Of Board From Five To Six Members
Brief: Avenue Therapeutics Provides Regulatory Update On IV Tramadol
Brief: Avenue Therapeutics Enters Into Agreement With Annji Pharmaceutical To Develop And Commercialize Aj201, For Treatment Spinal And Bulbar Muscular Atrophy
Brief: Avenue Therapeutics Inc- As Of September 30, 2022, Avenue's Cash And Cash Equivalents Totaled $0.2 Million
U.S. STOCKS ON THE MOVE-First Wave BioPharma, Energy firms, Brookdale Senior Living
U.S. STOCKS ON THE MOVE-Cano Health, DexCom, Conagra Brands
U.S. STOCKS ON THE MOVE-Akero, Ambac, Aptorum
Avenue Therapeutics slumps on $12 mln public offering of shares
Brief: Avenue Therapeutics Announces Pricing Of $12 Million Underwritten Public Offering
U.S. STOCKS ON THE MOVE-Arcutis Biotherapeutics, Chegg, Li Auto
U.S. STOCKS ON THE MOVE-Costco, FedEx, Coinbase, Exxon
Avenue Therapeutics climbs on reverse stock split, painkiller update
Brief: Avenue Therapeutics Says On August 1, Board Appointed Alexandra Maclean To Serve As CEO
Brief: Avenue Therapeutics - On May 24, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq - Filing
Brief: Avenue Therapeutics Appoints David Jin As Interim Principal Financial Officer